Newly Diagnosed With CLL: First Steps

Chronic lymphocytic leukemia is a cancer of B lymphocytes, one type of white blood cell. The cells accumulate in the blood, marrow, lymph nodes, and spleen. Most are functionally useless, which is why infections become more common even when the white count looks high.

CLL is common as leukemias go. For 2026 the American Cancer Society projects 22,760 new US cases and 4,350 deaths; SEER hosts that projection rather than producing it. NCI's measured SEER figures put the median age at diagnosis at 71 and five-year relative survival at 90.2 percent, based on people diagnosed between 2016 and 2022.

Many people are diagnosed by accident, from a routine blood count taken for something else. That is normal, not a sign that something was missed.

Ask which of these have been done. Some are prognostic, meaning they predict behavior, and some directly change drug choice.

FISH for chromosome changes. This looks for deletions and additions, including del(17p), trisomy 12, and t(11;14). Del(17p) is the one that matters most for treatment.

TP53 sequencing. Del(17p) usually travels with a TP53 mutation. Together they predict poor response and short duration of response to standard options. In one prospective trial, median overall survival with del(17p) was 7 years, the most unfavorable group.

IGHV mutation status. This asks whether the immunoglobulin heavy chain gene has undergone normal mutation. Unmutated IGHV predicts a more aggressive course.

Beta-2-microglobulin. A blood protein. Higher levels predict a worse course.

Lymphocyte doubling time. If the white count doubles in less than a year, the outlook is worse. This one requires several blood counts over time, which is a reason not to skip monitoring visits.

CLL has no single standard staging system. Two are used side by side.

The Rai system runs from 0 to IV:

• Stage 0: high lymphocyte count above 15,000 per cubic millimeter, with no enlarged nodes, no enlarged liver or spleen, no anemia, no low platelets.
• Stage I: adds enlarged lymph nodes.
• Stage II: adds an enlarged liver or spleen, with or without nodes.
• Stage III: adds anemia, hemoglobin under 11 g/dL.
• Stage IV: adds platelets under 100,000 per cubic millimeter.

The Binet system counts lymphoid areas, meaning neck, armpit, groin, and spleen:

• Stage A: no anemia or low platelets, and fewer than three lymphoid areas involved.
• Stage B: no anemia or low platelets, but three or more areas involved.
• Stage C: anemia or low platelets, regardless of how many areas.

Notice what both systems have in common. The jump to the worst stage comes from bone marrow failure, not from node size. Big nodes alone do not make advanced disease.

This is the hardest part of a CLL diagnosis to accept. For people who have no symptoms or only minimal ones, observation is standard, and treatment is deferred until the disease progresses and symptoms appear.

This is not neglect. No non-transplant treatment has been shown to cure CLL, and the stated goal of therapy is to get the most benefit with the least short-term and long-term harm. Starting drugs earlier in someone who is well has not been shown to help.

But watchful waiting means frequent monitoring, not disappearing. Ask exactly how often you will have blood counts and be examined, and what result would trigger treatment.

The FDA has approved ibrutinib, acalabrutinib, and venetoclax for first-line use in newly diagnosed CLL that needs treatment. Ibrutinib and acalabrutinib are BTK inhibitors, taken as pills, which block a signaling enzyme the CLL cell depends on. Venetoclax blocks BCL-2, a protein that keeps CLL cells from dying.

For people with poor-risk features, especially del(17p) or a TP53 mutation, these targeted drugs should be considered rather than chemotherapy.

There is a specific reason to prefer them. Older chemotherapy drugs such as fludarabine, bendamustine, cyclophosphamide, and chlorambucil work by damaging DNA. That damage can push the disease into a more aggressive and treatment-resistant form at relapse, and it can cause second cancers.

If a BTK inhibitor is chosen, heart rhythm is worth asking about. In a randomized trial with 41 months of median follow-up, atrial fibrillation occurred in 9.4 percent of people on acalabrutinib compared with 16 percent on ibrutinib.

In 2 to 10 percent of people, CLL transforms into an aggressive lymphoma, usually diffuse large B-cell lymphoma. This is called Richter transformation.

PET-CT is not part of routine CLL monitoring. It is used specifically when there are recurrent fevers, drenching night sweats, weight loss of more than 10 percent of body weight in 6 months, or rapidly enlarging lymph nodes. In one review of 432 patients, 209 had a maximum SUV of 5 or higher, and 80 percent of those had either aggressive CLL or Richter syndrome. Where the SUV was 10 or higher, 5-year overall survival was 30 percent.

Those four symptoms are worth memorizing. They are the ones that should prompt a call rather than waiting for the next scheduled visit.

• Call 911 or go to an emergency department if you cannot stop bleeding, or breathing becomes hard at rest, or you feel faint with a racing pulse. On a BTK inhibitor, add chest pain, fainting, or a sudden run of palpitations to that list, since atrial fibrillation is a known effect.
• Call your care team the same day if your temperature sits at 100.4°F (38°C) or above and you are on watchful waiting or a BTK inhibitor. CLL leaves you short of working antibodies even before any drug is started, so an infection deserves a call rather than a wait.
• Call 911 or go to an emergency department if that same temperature turns up while you are on chemotherapy such as bendamustine, fludarabine or chlorambucil, or in the first weeks of venetoclax while the dose is being stepped up. These knock the neutrophil count down, and a fever then is an emergency rather than a message left with the clinic.
• Call your care team the same day if new bruises appear, tiny red dots spread across your skin, or a cut keeps oozing.
• Call your care team within a day or two if any of the four transformation signals show up: repeated fevers with no infection behind them, night sweats that soak the bedclothes, losing more than a tenth of your body weight over about six months without trying, or a lymph node that visibly enlarges over a few weeks. These are the findings that prompt a PET-CT rather than a routine review.
• Call your care team within a day or two if ordinary activity leaves you breathless, or fatigue steps down a level, since both can signal falling blood counts.

Chronic Lymphocytic Leukemia (CLL), What Does Flow Cytometry Mean?, What Does a TP53 Mutation Mean?, and Active Surveillance vs Treatment.

• https://www.cancer.gov/types/leukemia/hp/cll-treatment-pdq
• https://seer.cancer.gov/statfacts/html/clyl.html